NCT04776395View on ClinicalTrials.gov

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2029

Conditions
Smoldering Plasma Cell Myeloma
Interventions
DRUG

Dexamethasone

Given PO

DRUG

Iberdomide Hydrochloride

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER

NCT04776395 - Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma | Biotech Hunter | Biotech Hunter